Home

RICHARD F POPS

CIK 1126490 · Director and CEO, Alkermes plc · last filed 2026-05-29

RICHARD F POPS is a Director and CEO, Alkermes plc who has filed 219 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for NBIX, was dated May 29, 2026. Across all open-market trades the lifetime net is −$140.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $65.3M across reported positions. 50 SEC filings were submitted jointly with NEUROCRINE BIOSCIENCES INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$65.31M

Companies

5

Total Filings

219

Lifetime Open-Market Net

-$140.30M

Filer Profile

Reported Address
CONNAUGHT HOUSE
1 BURLINGTON ROAD
DUBLIN 4, L2 D04 C5Y6
State of Incorporation
DE
Related Filers
NEUROCRINE BIOSCIENCES INC — 50 joint filings, latest 2026-05-29
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NBIX Director 37,798 $146.23 $5.53M -$13.18M 39 2026-05-29
ALKS Director and CEO, Alkermes plc 1,377,740 $43.39 $59.78M -$125.56M 158 2026-03-04
Epizyme, Inc. (EPZM) Delisted Director — $1.47 — $0 8 2020-06-02
ACCELERON PHARMA INC (XLRN) Delisted Director 32,500 $178.75 $5.81M -$1.55M 8 2019-01-29
EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted Director — — — $0 2 2008-06-02

Recent Filings

219 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-05-29 NBIX Grant (A) — $0 EDGAR
2026-05-21 NBIX Exer (M) +3,318 $0 EDGAR
2026-05-18 NBIX Mixed — -$1.65M EDGAR
2026-05-15 NBIX Notice (144) −15,000 -$2.39M EDGAR
2026-03-04 ALKS Grant (A) — $0 EDGAR
2026-02-06 ALKS Mixed +87,350 -$2.09M EDGAR
2025-05-22 NBIX Mixed +2,869 $0 EDGAR
2025-02-20 ALKS Grant (A) — $0 EDGAR
2025-02-07 ALKS Mixed +110,715 -$2.51M EDGAR
2024-05-23 NBIX Grant (A) — $0 EDGAR
Showing 1–10 of 219
Page 1 of 22
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.